Anakinra

Active ingredient description

Anakinra neutralises the biologic activity of interleukin-1α (IL-1α) and interleukin-1β (IL-1β) by competitively inhibiting their binding to interleukin-1 type I receptor (IL-1RI). Interleukin-1 (IL-1) is a pivotal pro-inflammatory cytokine mediating many cellular responses including those important in synovial inflammation.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
L04AC03
Anakinra
L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC03

Medicines

Anakinra is the active ingredient of these drugs:

Drug
Countries
KINERET

Australia Austria Canada Cyprus Estonia

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
KINERET Solution for injection
Summary of Product Characteristics (SPC)

3D molecular structure

3D representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

9013DUQ28K - ANAKINRA

CAS registry number

143090-92-0 - anakinra

SNOMED-CT

385549000 - Anakinra (substance)

 
Next: Usage >